A dual GIP and GLP-1 receptor agonist approved for type 2 diabetes and obesity.
INTRODUCTION: For the last three decades, bariatric/metabolic surgeries have highlighted the relevance of certain gastrointestinal hormones in controlling and regulating glucose metabolism. The incretins have been a significant focus in developing th…
The approvals of semaglutide and tirzepatide have set new benchmarks in the treatment of type 2 diabetes and obesity. Building on their success, novel glucagon-like peptide-1 (GLP-1)-based therapeutics are rapidly advancing. These next-generation age…
Obesity in women over 65 represents a growing clinical challenge, particularly due to its association with increased risks of cardiovascular disease, osteoarthritis, frailty, sleep-breathing disorders, and sarcopenia. The prevalence of obesity in thi…
BACKGROUND: Cocaine use disorder (CUD) remains among the most treatment-resistant addictions, characterised by high relapse rates even following extended abstinence periods. Dopamine signalling in mesocorticolimbic circuits contributes to cocaine's r…
The growing use of glucagon-like peptide-1 (GLP-1) receptor agonists and dual GIP/GLP-1 agonists has intensified debate over the role of pharmacotherapy in addressing obesity. While these drugs can support short-term weight loss, access remains limit…
INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for weight management. Although generally well-tolerated, these agents may alter the pharmacokinetics of concurrently administered medications. CASE PRESE…
Type 2 diabetes mellitus is closely associated with male reproductive dysfunction driven by oxidative stress, hormonal imbalance, and testicular cell damage. This study evaluated the effects of tirzepatide, a dual agonist of the glucose-dependent ins…
INTRODUCTION: Bariatric surgery is the most effective treatment modality for individuals with morbid obesity, providing significant and durable weight loss and comorbidity resolution. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotrop…
Lipedema is a chronic, progressive adipose tissue disorder characterized by disproportionate subcutaneous fat accumulation, pain, edema, and resistance to conventional weight-loss strategies. Although traditionally conceptualized as a disease of adip…
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly used for weight management and cardiometabolic health. Common peroneal neuropathy (CPN) associated with rapid weight loss is attributed to adipose tissue reduction and subsequent n…
BACKGROUND AND OBJECTIVES: Little is known about glucagon-like peptide-1 receptor agonists (GLP1RAs) use in multiple sclerosis. We described the frequency and characteristics associated with use. METHODS: A cross-sectional survey of NARCOMS Registry…
OBJECTIVE: This study summarizes the evidence on the clinical effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in adults with idiopathic intracranial hypertension (IIH). BACKGROUND: IIH is characterized by elevated intracranial pressu…
OBJECTIVES: Diabetes mellitus, including new-onset diabetes after transplant, is a prevalent complication in solid-organ transplant recipients, often necessitating complex glycemic management. Glucagon-like peptide-1 receptor agonists, including sema…
Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), dipeptidyl peptidase-4 inhibitors (DPP-4is), and the dual GIP/GLP-1 RA tirzepatide, are widely prescribed for type 2 diabetes mellitus (T2DM). Their musculoske…
Heart failure with preserved ejection fraction (HFpEF) represents approximately half of all heart failure cases and poses a growing global health challenge driven by an ageing population and an increasing comorbidity burden. Once regarded as a condit…
OBJECTIVE: To evaluate two-year costs to insured patients treated with Roux-en-Y gastric bypass (RYGB) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for type 2 diabetes (T2D) and obesity. METHODS: Using the 2017 to 2023 Merative™ claims da…
AIM: This study used a network meta-analysis (NMA) as the primary approach to compare the efficacy and tolerability of GLP-1 receptor agonists and dual agonists in overweight or obese adults with and without Type 2 diabetes. MATERIALS AND METHODS: Pu…
AIMS: Evidence suggests sodium glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists may reduce the onset/progression of dementia. The effect of the dual GLP1/GIP receptor agonist tirzepatide on dementia outcomes remains u…
BACKGROUND: The increasing use of GLP-1 receptor agonists for weight loss and metabolic improvements has led to the recognition of various side effects. One potential, yet underexplored, adverse effect is hair loss. This study aims to investigate the…